Participants:18–64 years · 65+ years
Substances:N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Registered drugNo placebo

Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Clear cell papillary renal cell carcinoma

Not recruiting

Registered drugNo placebo

Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Chronic myeloid leukaemia

Not recruiting

Registered drugNo placebo

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Nilotinib

Contact Research Centre

Evaluating Higher Dose Nusinersen in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam

Not recruiting

InvestigationalNo placebo

Evaluating Higher Dose Nusinersen in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Nusinersen

Contact Research Centre

Crohn's disease

Not recruiting

Investigational

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Risankizumab

Contact Research Centre

Colitis ulcerative

Not recruiting

Investigational

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Risankizumab

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Registered drugNo placebo

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Everolimus

Contact Research Centre

Find therapies in clinical trials near you – page 40

574 trials match your criteria

Paroxysmal nocturnal haemoglobinuria

Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Hepatocellular carcinoma

Study of Durvalumab, Tremelimumab, and Bevacizumab for Patients with Non-Resectable Liver Cancer

Growth hormone deficiency

Study on the Effects of Somapacitan and Somatropin in Children with Growth Hormone Deficiency

Mantle cell lymphoma

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Parkinson's disease

Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease

Hepatocellular carcinoma

Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation

Clear cell papillary renal cell carcinoma

Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Chronic myeloid leukaemia

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Evaluating Higher Dose Nusinersen in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam

Evaluating Higher Dose Nusinersen in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam

Crohn's disease

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Colitis ulcerative

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Gastroenteropancreatic neuroendocrine tumour disease

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.